专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110002888A1 Albumin Fusion Proteins 有权
公开(公告)号：US20110002888A1
公开(公告)日：2011-01-06
申请号：US12793658
申请日：2010-06-03
申请人： Craig A. Rosen , Adam Bell , Paul A. Moore , Yanggu Shi , David Lafleur , Jason B. Bock , Michael W. Laird , William A. Haseltine , Douglas B. Woods , Mani Subramanian
发明人： Craig A. Rosen , Adam Bell , Paul A. Moore , Yanggu Shi , David Lafleur , Jason B. Bock , Michael W. Laird , William A. Haseltine , Douglas B. Woods , Mani Subramanian
IPC分类号： A61K38/21 , C07K14/76 , A61K38/38 , C07H21/00 , C12N15/63 , C12N5/10 , A61K38/46 , A61K38/18 , A61K38/22 , A61K39/395 , A61K38/43 , C12N9/96 , A61K39/12 , A61K38/30 , A61P35/00 , A61P3/04 , A61P3/10 , A61P3/00 , A61P37/02 , A61P9/08 , A61P9/00 , A61P9/04 , A61P1/16 , A61P25/30 , A61P31/12 , A61P9/12
CPC分类号： C07K14/58 , C07K14/765 , C07K2319/01
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

2. 发明申请

US20100093627A1 ALBUMIN FUSION PROTEINS 有权
公开(公告)号：US20100093627A1
公开(公告)日：2010-04-15
申请号：US12534585
申请日：2009-08-03
申请人： Craig A. Rosen , William A. Haseltine , Steven M. Ruben
发明人： Craig A. Rosen , William A. Haseltine , Steven M. Ruben
IPC分类号： A61K38/38 , C12N15/63 , C12N5/00 , C12N1/19 , C12N5/07 , C12P21/00 , C07K14/76 , A61P3/00 , A61P37/06
CPC分类号： C07K14/765 , A61K38/00 , C07K2319/31 , C07K2319/35 , C12N15/62
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

3. 发明申请

US20080153751A1 Albumin Fusion Proteins 有权
公开(公告)号：US20080153751A1
公开(公告)日：2008-06-26
申请号：US11929828
申请日：2007-10-30
申请人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
发明人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
IPC分类号： A61K38/00 , C07K16/00 , C07H21/04 , C12N5/00 , A61P43/00 , C12N5/02 , C12P21/04
CPC分类号： C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

4. 发明申请

US20080146503A1 Albumin Fusion Proteins 有权
公开(公告)号：US20080146503A1
公开(公告)日：2008-06-19
申请号：US11772643
申请日：2007-07-02
申请人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
发明人： Craig A. Rosen , William A. Haseltine , David J. Ballance , Andrew J. Turner , Steven M. Ruben
IPC分类号： A61K38/00 , A61P43/00 , C07K14/76 , C12N15/00 , C12N15/11 , C12N5/06
CPC分类号： C07K14/765 , A61K31/155 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K38/00 , A61K38/04 , A61K38/17 , A61K38/28 , A61K39/21 , C07K7/06 , C07K14/005 , C07K14/435 , C07K14/4713 , C07K14/4723 , C07K14/475 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/55 , C07K14/555 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/57563 , C07K14/5759 , C07K14/585 , C07K14/59 , C07K14/60 , C07K14/605 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/655 , C07K14/665 , C07K14/705 , C07K14/7151 , C07K14/82 , C07K16/00 , C07K16/241 , C07K16/26 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/20 , C07K2319/30 , C07K2319/31 , C12N7/00 , C12N9/0006 , C12N9/0008 , C12N15/62 , C12N2501/335 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y101/01105 , C12Y102/01 , C12Y207/01095
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

5. 发明授权

US07189690B2 Albumin fusion proteins 有权
公开(公告)号：US07189690B2
公开(公告)日：2007-03-13
申请号：US10775180
申请日：2004-02-11
申请人： Craig A. Rosen , William A. Haseltine
发明人： Craig A. Rosen , William A. Haseltine
IPC分类号： C07K14/00
CPC分类号： C07K14/76 , C07K14/4713 , C07K14/765 , C07K2319/00 , C12N15/62
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

6. 发明授权

US06905688B2 Albumin fusion proteins 有权
公开(公告)号：US06905688B2
公开(公告)日：2005-06-14
申请号：US09833118
申请日：2001-04-12
申请人： Craig A. Rosen , William A. Haseltine
发明人： Craig A. Rosen , William A. Haseltine
IPC分类号： C12N15/09 , A61K35/12 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/23 , A61K38/27 , A61K38/28 , A61K38/43 , A61K38/46 , A61K38/48 , A61K38/55 , A61K39/00 , A61K39/395 , A61K47/48 , A61K48/00 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P3/14 , A61P5/00 , A61P5/10 , A61P5/14 , A61P5/40 , A61P7/00 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/00 , A61P13/02 , A61P13/08 , A61P13/12 , A61P15/00 , A61P15/08 , A61P15/10 , A61P15/18 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/12 , A61P17/14 , A61P19/00 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/16 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/00 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , A61P33/02 , A61P33/06 , A61P33/12 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P39/02 , A61P41/00 , A61P43/00 , C07K14/47 , C07K14/55 , C07K14/56 , C07K14/565 , C07K14/585 , C07K14/60 , C07K14/61 , C07K14/62 , C07K14/635 , C07K14/65 , C07K14/705 , C07K14/715 , C07K14/745 , C07K14/75 , C07K14/76 , C07K14/765 , C07K14/81 , C07K16/00 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/02 , C12N5/10 , C12N9/14 , C12N9/74 , C12N9/99 , C12N15/62
CPC分类号： A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

7. 发明授权

US06620619B2 Human DNA mismatch repair protein 失效
标题翻译：人类DNA错配修复蛋白
公开(公告)号：US06620619B2
公开(公告)日：2003-09-16
申请号：US08210143
申请日：1994-03-16
申请人： William A. Haseltine , Steven Ruben , Ying-Fei Wei , Mark D. Adams , Robert D. Fleischmann , Claire M. Fraser , Craig A. Rosen , Rebecca A. Fuldner , Ewen F. Kirkness
发明人： William A. Haseltine , Steven Ruben , Ying-Fei Wei , Mark D. Adams , Robert D. Fleischmann , Claire M. Fraser , Craig A. Rosen , Rebecca A. Fuldner , Ewen F. Kirkness
IPC分类号： G01N3306
CPC分类号： C07K14/47
摘要： The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.
摘要翻译：本发明公开了三种人类DNA修复蛋白和编码这种蛋白质的DNA（RNA）。 DNA修复蛋白可以通过重组DNA技术产生。人类DNA修复蛋白之一hmlh1已被绘制在染色体3上.DNA修复蛋白的多核苷酸序列可用于诊断遗传性对癌症的易感性。

8. 发明授权

US06482606B1 Human DNA mismatch repair polynucleotides 失效
标题翻译：人DNA错配修复多核苷酸
公开(公告)号：US06482606B1
公开(公告)日：2002-11-19
申请号：US08187757
申请日：1994-01-27
申请人： Mark D. Adams , Robert D. Fleischmann , Claire M. Fraser , Rebecca A. Fuldner , Ewen F. Kirkness , William A. Haseltine , Craig A. Rosen , Steve Ruben , Ying-Fei Wei
发明人： Mark D. Adams , Robert D. Fleischmann , Claire M. Fraser , Rebecca A. Fuldner , Ewen F. Kirkness , William A. Haseltine , Craig A. Rosen , Steve Ruben , Ying-Fei Wei
IPC分类号： C12P2102
CPC分类号： C07K14/47
摘要： The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.
摘要翻译：本发明公开了三种人类DNA修复蛋白和编码这种蛋白质的DNA（RNA）。 DNA修复蛋白可以通过重组DNA技术产生。人类DNA修复蛋白之一hmlh1已被绘制在染色体3上.DNA修复蛋白的多核苷酸序列可用于诊断遗传性对癌症的易感性。

9. 发明授权

US4981790A Stable TatIII cell lines, TatIII gene products, and assay methods 失效
公开(公告)号：US4981790A
公开(公告)日：1991-01-01
申请号：US806263
申请日：1985-12-06
申请人： William A. Haseltine , Craig A. Rosen , Joseph G. Sodroski , Wei C. Goh
发明人： William A. Haseltine , Craig A. Rosen , Joseph G. Sodroski , Wei C. Goh
IPC分类号： C12P19/34 , C07K14/15 , C07K14/16 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/85 , C12P21/00 , C12R1/91
CPC分类号： C07K14/005 , C12N15/85 , C12N2740/14022 , C12N2740/16322
摘要： This invention describes stable tat.sub.III cell lines. It is disclosed that by transfecting a preselected tat.sub.III cell line with a vector containing a sufficient amount of the HTLV-III LTR responsive to tat.sub.III gene products for trans-activation and an enhancer upstream of the tat.sub.III responsive segment, it is possible to express high levels of the tat.sub.III gene products. By including a preselected heterologous gene on this vector, it is also possible to express high levels of a desired gene product. A substantially pure protein comprising 86 amino acids and having an apparent molecular weight of about 14,000 dalton and exhibiting trans-activating activity is also disclosed. This protein and polypeptides having trans-activating ability, which is also disclosed, can be used to produce high levels of a desired gene product. A method of detecting the presence of HTLV-III/LAV virus in an individual is also disclosed and comprises the step of:(a) incubating whole blood or lymphocytes from the invididual to be tested with tat.sub.III cell lines of the present invention in a culture medium; and(b) screening for cytopathic effects on the cells is also disclosed. A method of screening for a compound that inhibits trans-activation of the tat.sub.III gene product is also disclosed and comprises the steps of:(1) transacting a tat.sub.III cell line of the present invention with a vector containing a gene that expresses a selectable marker and whose expression is under the control of an HTLV-III LTR;(2) transfecting the same type of tat.sub.III cell lines as in step (1) with the selectable gene chosen in step (1) but under the control of a different regulatory sequence;(3) thereafter, adding a preselected compound to each of the cell lines in increasing concentrations; and(4) measuring the expression of the selectable gene product to determine whether the compound effects the tat.sub.III function without being toxic to the cell.

10. 发明授权

US4738922A Trans-acting transcriptional factors 失效
标题翻译：转录因子
公开(公告)号：US4738922A
公开(公告)日：1988-04-19
申请号：US614297
申请日：1984-05-25
申请人： William A. Haseltine , Joseph G. Sodrowski , Craig A. Rosen
发明人： William A. Haseltine , Joseph G. Sodrowski , Craig A. Rosen
IPC分类号： C12P19/34 , C07K14/15 , C07K14/16 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/85 , C12P21/00 , C12R1/91 , C12N1/00 , C12N7/00
CPC分类号： C07K14/005 , C12N15/85 , C12N2740/14022 , C12N2740/16322
摘要： This invention describes the discovery of a novel phenomena in retrovirus transcription, namely transcriptional trans-activation. Described herein are novel trans-acting factors which may be employed to enhance the production of heterologous genes. Described is a novel trans-acting directing gene, designated herein as the "luk" gene and the 35,000 to 45,000, more specifically about 42,000 dalton molecular weight protein encoded thereby.The present invention demonstrates the LTR elements of HTLV can function as transcriptional promoters for heterologous genes on both unintegrated and integrated DNA. In general, the HTLV-1 LTR is a stronger promoter than is the HLTV-II LTR in its requirements for cellular and/or viral trans-acting factors in order to function efficiently. HTLV infection results in the production of trans-acting factors that dramatically increase the rate of HTLV LTR-promoted transcription.
摘要翻译：本发明描述了逆转录病毒转录中的新现象的发现，即转录反式激活。本文描述了可用于增强异源基因产生的新型反式作用因子。描述了一种新型的反式作用指导基因，其在本文中称为“luk”基因，并且由此编码的35,000至45,000，更具体地约42,000道尔顿分子量蛋白。本发明证明了HTLV的LTR元件可以作为非整合和整合的DNA上异源基因的转录启动子。一般来说，HTLV-1 LTR比HLTV-II LTR在细胞和/或病毒反式作用因子方面的要求更强，以有效发挥作用。 HTLV感染导致反式作用因子的产生，其显着增加了HTLV LTR促进转录的速率。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式